FDA Advisory Panel Narrowly Votes Against New ALS Drug
In a close vote, an advisory panel for the US Food and Drug Administration decided not to recommend the approval of an experimental drug for amyotrophic lateral sclerosis (ALS).
In a close vote, an advisory panel for the US Food and Drug Administration decided not to recommend the approval of an experimental drug for amyotrophic lateral sclerosis (ALS).
AMX0035 is an oral, fixed-dose coformulation of sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine.
Researchers sought to determine the effect GBA variants have on cognitive status in patients with amyotrophic lateral sclerosis.
Researchers sought to investigate the association between serum asymmetric dimethylarginine (ADMA) levels and the progression and prognosis of amyotrophic lateral sclerosis, and to compare cerebrospinal fluid and serum ADMA levels with other ALS biomarkers.
Researchers sought to estimate incidence rates and case counts of amyotrophic lateral sclerosis in the US from 2014 through 2016 using administrative and self-reported databases.
Researcher sought to assess the incidence and mortality from ALS in NFL athletes and to describe the characteristics associated with ALS incidence in this cohort.
Researchers sought to compare various high-caloric food supplements as add-on therapy to normal food intake and standard treatment in patients with ALS.
Researchers sought to assess the loss of insight related to behavioral changes across cognitive profiles in amyotrophic lateral sclerosis subgroups.
AMX0035 is an oral, fixed-dose coformulation of sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine.
Using similarity network fusion and spectral clustering, researchers sought to identify ALS disease subphenotypes and whether different patterns of disruption are predictive of outcome.